[Inhibitory effect of prolactin secretion by luteinizing hormone releasing hormone agonist (buserelin)]

Inoue T, T Inoue, R Matsuoka, Matsuoka R, H Mori, Mori H, Kigawa T, T Kigawa
Nihon Naibunpi Gakkai zasshi · 1986 · doi:10.1507/endocrine1927.62.6_745 · PMID:3093292
other OA: bronze public-domain-us
🔓 Open OA copy Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-02 ⓘ

Buserelin administration to endometriosis patients significantly inhibited LH, FSH, and prolactin secretion, with prolactin inhibition dose- and duration-dependent and likely mediated by direct CNS activity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-13 · read from full text ⓘ

This study investigated the effects of continuous intranasal administration of the luteinizing hormone-releasing hormone agonist buserelin on prolactin secretion in five patients diagnosed with endometriosis. The researchers observed that buserelin effectively treated clinical symptoms while markedly inhibiting the secretion of both luteinizing hormone and follicle-stimulating hormone under stimulation tests. Additionally, prolactin levels were significantly reduced in a dose- and duration-dependent manner, with no correlation found between estradiol and prolactin levels during treatment. These results indicate that buserelin suppresses prolactin through direct central nervous system activity rather than indirectly via estrogen suppression. This paper is centrally about endometriosis — specifically evaluating the hormonal mechanisms by which buserelin exerts its therapeutic effect on the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The LH RH agonist Buserelin was continuously administered through the nose over an extended period to 5 patients with endometriosis at daily doses ranging between 300 micrograms and 1,200 micrograms. The clinical findings and endocrinological dynamics, with emphasis on PRL secretion function, were investigated and the findings below were obtained. The clinical findings showed Buserelin to be effective against endometriosis. The administration of Buserelin markedly inhibited the secretion of LH and FSH under LH-RH loading. The administration of Buserelin markedly inhibited the secretion of PRL and the degree of inhibition appeared to be dependent on the dose and duration of Buserelin administration. No correlation between E2 and PRL was observed during Buserelin administration. The findings suggest that Buserelin inhibits PRL secretion by direct CNS activity, not indirectly through inhibition of E2 production.
Full text 1,591 characters · extracted from oa-doi-fallback · click to expand
LHRHagonist (Buserelin) のPRL分泌抑制作用 1986 年 62 巻 6 号 p. 745-753 詳細 抄録 The LH RH agonist Buserelin was continuously adminstered through the nose over an extended period to 5 patients with endometriosis at daily doses ranging between 300μg and 1,200μg. The clinical findings and endocrinological dynamics, with emphasis on PRL secretion function, were investigated and the findings below were obtained. 1. The clinical findings showed Buserelin to be effective against endometriosis. 2. The administration of Buserelin markedly inhibited the secretion of LH and FSH under LH-RH loading. 3. The administration of Buserelin markedly inhibited the secretion of PRL and the degree of inhibition appeared to be dependent on the dose and duration of Buserelin administration. 4. No correlation between E2 and PRL was observed during Buserelin administration. 5. The findings suggest that Buserelin inhibits PRL secretion by direct CNS activity, not indirectly through inhibition of E2 production. 1. The clinical findings showed Buserelin to be effective against endometriosis. 2. The administration of Buserelin markedly inhibited the secretion of LH and FSH under LH-RH loading. 3. The administration of Buserelin markedly inhibited the secretion of PRL and the degree of inhibition appeared to be dependent on the dose and duration of Buserelin administration. 4. No correlation between E2 and PRL was observed during Buserelin administration. 5. The findings suggest that Buserelin inhibits PRL secretion by direct CNS activity, not indirectly through inhibition of E2 production. © 一般社団法人 日本内分泌学会

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Buserelin Prolactin Administration, Intranasal Adult Buserelin Buserelin Depression, Chemical Endometriosis Endometriosis Endometriosis Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone Luteinizing Hormone Prolactin Uterine Neoplasms Uterine Neoplasms Uterine Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-21T06:14:13.963979+00:00
pubmed
last seen: 2026-05-13T22:09:35.489789+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine